September 11th 2025
HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
ABP 980 Exhibits Comparable Safety and PK Profile to Reference Trastuzumab
August 16th 2017A phase 1 trial of ABP 980, Amgen’s proposed biosimilar of reference trastuzumab (Herceptin), demonstrated ABP 980’s pharmacokinetic similarity to both US-approved reference trastuzumab and European Union-approved reference trastuzumab. Amgen and Allergan have submitted applications for approval of ABP 980 with both the FDA and the European Medicines Agency.
Supportive Care in Oncology Therapy: Pegfilgrastim Biosimilars in the Pipeline
December 7th 2016Pegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.